Starczynowski Lab

Publications

Sutter, PJ; Walker, MM; Finocchio, CJ; Jiang, J-K; Tawa, GJ; Zhang, X; Xu, X; Shah, P; Gomba, GY; Starczynowski, DT; Thomas, CJ; Hoyt, S. Optimization of IRAK1/4/pan-FLT3 kinase inhibitors as treatments for acute myeloid leukemia. Bioorganic and Medicinal Chemistry Letters. 2025; 129:130355.

Jones, L; Khadaroo, A; Tiwari, R; Choi, K; Adam, M; Wunderlich, M; Stillwell, C; Sexton, C; Seibel, W; Tawa, G; Hoyt, S; Thomas, C; Starczynowski, D. FLT3-F691L confers kinase-independent resistance via Grb2-dependent MAPK signaling in AML. Blood. 2025; 146(Supplement 1):5049-5049.

Anandappa, A; Trivedi, V; Bones, M; Raval, J; Hefner, R; Wooten, A; Bowman, R; Levine, R; Starczynowski, D; Miles, L. RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977. Blood. 2025; 146(Supplement 1):3229-3229.

Vick, EJ; Starczynowski, DT. IRAK signaling in cancers: mechanisms, targeting, and clinical implications. Expert Opinion on Investigational Drugs. 2025; 34(10):775-792.

Vick, EJ; Hassan, A; Choi, K; Bennett, J; Muto, T; Clough, CA; Culver-Cochran, AE; Hueneman, K; Bolanos, LC; Wunderlich, M; Klumpp-Thomas, C; Greis, KD; Thomas, CJ; Starczynowski, DT. Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization. Leukemia. 2025; 39(9):2163-2173.

Clough, CA; Cunningham, C; Philbrook, SY; Hueneman, KM; Sampson, AM; Choi, K; Greis, KD; Starczynowski, D. Characterization of E1 enzyme dependencies in mutant-UBA1 human cells reveals UBA6 as a novel therapeutic target in VEXAS syndrome. Leukemia. 2025; 39(8):1997-2009.

Mestre, J; Chaparro-González, L; Granada, I; Mallo, M; Cid, E; Mancini, E; Calvete, O; Risueño, RM; Starczynowski, DT; Solé, F. Integrated cytogenetic and genomic profiling of the MDS-L cell line. Molecular Cytogenetics. 2025; 18(1):11.

Agarwal, P; Sampson, A; Hueneman, K; Choi, K; Jakobsen, NA; Uible, E; Ishikawa, C; Yeung, J; Bolanos, L; Zhao, X; Galloway-Pena, J; Byrd, JC; Vyas, P; Starczynowski, DT. Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1. Nature. 2025; 642(8066):201-211.

Vick, EJ; Walulik, S; Sampson, A; Hassan, A; Wunderlich, M; Volk, A; Starczynowski, D. The IRAK4 long isoform as widely upregulated in non-splicesome mutated acute myeloid leukemia and as altered by hypomethylating agent therapy. Journal of Clinical Oncology. 2025; 43(16_suppl):6524-6524.

Ishikawa, C; Barreyro, L; Sampson, AM; Hueneman, KM; Choi, K; Philbrook, SY; Choi, I; Bolanos, LC; Wunderlich, M; Volk, AG; Watowich, SS; Greis, KD; Starczynowski, DT. Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia. Journal of Clinical Investigation. 2025; 135(10).

Hoyt, SB; Finocchio, CJ; Croll, E; Tawa, GJ; Zhang, M; Wang, J; Li, H; Ma, L; Li, K; Zhang, X; Culver-Cochran, AE; Rosenbaum, JS; Starczynowski, DT; Thomas, CJ. IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2025; 16(5):887-895.

Venkatasubramanian, M; Schwartz, L; Ramachandra, N; Bennett, J; Subramanian, KR; Chen, X; Gordon-Mitchell, S; Fromowitz, A; Pradhan, K; Shechter, D; Grimes, HL; Starczynowski, DT; Verma, A; Salomonis, N. Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias. Science Translational Medicine. 2025; 17(797):eadr1471.

Babic, I; Bryan, N; Cunningham, C; Sampson, A; Starczynowski, D; Nurmemmedov, E. Abstract 5480: Live cell real-time quantification of drug-target engagement for rapid drug discovery. Cancer Research. 2025; 85(8_Supplement_1):5480-5480.

Borate, U; Pugh, K; Waller, A; Welkie, RL; Huang, Y; Bewersdorf, JP; Stahl, M; Dezern, AE; Platzbecker, U; Sekeres, MA; Bennett, JM; List, AF; Brunner, AM; Zeidan, AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025; 145(13):1369-1381.

Wang, Y; Xiu, Y; Dong, Q; Zhao, J; Neumbo, K; Miyagi, M; Borcherding, N; Fu, L; De Celis, H; Pintozzi, N; Starczynowski, DT; Zhao, C. TIFAB modulates metabolic pathways in KMT2A::MLLT3-induced AML through HNF4A. Blood advances. 2025; 9(4):844-855.

Aggarwal, RK; Sidoli, S; Wang, J; Sahu, S; Sanawar, R; Gupta, V; Aluri, S; Sukrithan, V; Vegivinti, CTR; Zavras, PD; Lafave, LM; Cheng, H; Verma, A; Zou, Y. Smoking-Associated Carcinogen-Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation. Clinical Cancer Research. 2025; 31(4):746-755.

Aakash, F; Gisriel, SD; Zeidan, AM; Bennett, JM; Bejar, R; Bewersdorf, JP; Borate, UM; Boultwood, J; Brunner, AM; Buckstein, R; Xie, Z; Xu, ML; Hasserjian, RP; Loghavi, S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology. 2024; 37(12):100615.

Hoyt, SB; Finocchio, CJ; Croll, E; Tawa, GJ; Li, H; Ma, L; Li, K; Liu, L; Li, R; Zhang, X; Culver-Cochran, AE; Rosenbaum, JS; Starczynowski, DT; Thomas, CJ. Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia. ACS Medicinal Chemistry Letters. 2024; 15(11):1843-1851.

Culver-Cochran, AE; Hassan, A; Hueneman, K; Choi, K; Ma, A; Vancauwenbergh, B; O'brien, E; Wunderlich, M; Perentesis, JP; Starczynowski, DT. Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. Nature Communications. 2024; 15(1):9189.

Stepanchick, E; Wilson, A; Sulentic, AM; Choi, K; Hueneman, K; Starczynowski, DT; Chlon, TM. DDX41 haploinsufficiency causes inefficient hematopoiesis under stress and cooperates with p53 mutations to cause hematologic malignancy. Leukemia. 2024; 38(8):1787-1798.

Barreyro, L; Sampson, AM; Hueneman, K; Choi, K; Christie, S; Ramesh, V; Wyder, M; Wang, D; Pujato, M; Greis, KD; Huang, G; Starczynowski, DT. Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML. iScience. 2024; 27(6):109809.

Laranjeira, ABA; Kong, T; Snyder, SC; Fulbright, MC; Fisher, DAC; Starczynowski, DT; Oh, ST. In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms. Blood. 2024; 143(23):2414-2424.

Matsui, S; Ri, C; Bolanos, LC; Choi, K; Shibamiya, A; Ishii, A; Takaishi, K; Oshima-Hasegawa, N; Tsukamoto, S; Takeda, Y; Yokote, K; Starczynowski, DT; Sakaida, E; Muto, T. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 2024; 38(5):1032-1045.

Riabov, V; Xu, Q; Schmitt, N; Streuer, A; Ge, G; Bolanos, L; Wunderlich, M; Jann, J-C; Wein, A; Altrock, E; Steiner, L; Jawhar, M; Hofmann, W-K; Nowak, D. ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms. Haematologica. 2024; 109(5):1426-1438.

Garcia-Manero, G; Platzbecker, U; Lim, K-H; Nowakowski, G; Abdel-Wahab, O; Kantarjian, H; Verma, A; Starczynowski, DT. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. Frontiers in Hematology. 2024; 3:1339870.

Xie, Z; Starczynowski, DT. Are DDX41 variants of unknown significance and pathogenic variants created equal? Haematologica. 2023; 108(11):2883-2885.

Stahl, M; Bewersdorf, JP; Xie, Z; Porta, MGD; Komrokji, R; Xu, ML; Abdel-Wahab, O; Taylor, J; Steensma, DP; Starczynowski, DT; Wei, AH; Santini, V; Savona, MR; Zeidan, AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews. 2023; 62:101128.

Gorak, EJ; Otterstatter, M; Al Baghdadi, T; Gillis, N; Foran, JM; Liu, JJ; Bejar, R; Gore, SD; Kroft, SH; Harrington, A; Walker, ME; Padron, E; Dezern, AE; Sekeres, MA. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood advances. 2023; 7(20):6120-6129.

Muto, T; Walker, CS; Agarwal, P; Vick, E; Sampson, A; Choi, K; Niederkorn, M; Ishikawa, C; Hueneman, K; Varney, M; Starczynowski, DT. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023; 108(10):2715-2729.

Bennett, J; Ishikawa, C; Agarwal, P; Yeung, J; Sampson, A; Uible, E; Vick, E; Bolanos, LC; Hueneman, K; Wunderlich, M; Rosenbaum, J; Hoyt, SB; Thomas, CJ; Starczynowski, DT. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood. 2023; 142(11):989-1007.

Dean, ST; Ishikawa, C; Zhu, X; Walulik, S; Nixon, T; Jordan, JK; Henderson, S; Wyder, M; Salomonis, N; Wunderlich, M; Greis, KD; Starczynowski, DT; Volk, AG. Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development. Blood advances. 2023; 7(17):4822-4837.

Marion, W; Koppe, T; Chen, C-C; Wang, D; Frenis, K; Fierstein, S; Sensharma, P; Aumais, O; Peters, M; Ruiz-Torres, S; Ebert, BL; Starczynowski, D; Da Rocha, EL; Rowe, RG. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia. Leukemia. 2023; 37(8):1698-1708.

Bewersdorf, JP; Xie, Z; Bejar, R; Borate, U; Boultwood, J; Brunner, AM; Buckstein, R; Carraway, HE; Churpek, JE; Daver, NG; Xu, ML; Savona, MR; Wei, AH; Zeidan, AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews. 2023; 60:101072.

Stahl, M; Abdel-Wahab, O; Wei, AH; Savona, MR; Xu, ML; Xie, Z; Taylor, J; Starczynowski, D; Sanz, GF; Sallman, DA; Steensma, DP; Sekeres, MA; Buckstein, RJ; Zeidan, AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood advances. 2023; 7(12):2709-2714.

Starczynowski, DT. 1031 – FROM PRE-LEUKEMIC STATES TO MALIGNANT TRANSFORMATION: UNRAVELING THE ROLE OF DYSREGULATED INNATE IMMUNE SIGNALING AND INFLAMMATION IN MYELOID MALIGNANCIES. Experimental Hematology. 2023; 124:s35.

Chlon, T; Stepanchick, E; Sulentic, A; Wilson, A; Starczynowski, D. 3040 – HETEROZYGOUS MUTATIONS IN DDX41 CAUSE ERYTHROID PROGENITOR CELL DEFECTS AND COOPERATE WITH P53 MUTATIONS TO CAUSE HEMATOLOGIC MALIGNANCY. Experimental Hematology. 2023; 124:s70.

Zeidan, AM; Bewersdorf, JP; Buckstein, R; Sekeres, MA; Steensma, DP; Platzbecker, U; Loghavi, S; Boultwood, J; Bejar, R; Bennett, JM; Savona, MR; Wei, AH; Abdel-Wahab, O; Santini, V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022; 36(12):2939-2946.

Yeaton, A; Cayanan, G; Loghavi, S; Dolgalev, I; Leddin, EM; Loo, CE; Torabifard, H; Nicolet, D; Wang, J; Corrigan, K; Tsirigos, A; Eisfeld, A-K; Aifantis, I; Guillamot, M. The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discovery. 2022; 12(10):2392-2413.

Choudhary, GS; Pellagatti, A; Agianian, B; Smith, MA; Bhagat, TD; Gordon-Mitchell, S; Sahu, S; Pandey, S; Shah, N; Aluri, S; Gavathiotis, E; Boultwood, J; Starczynowski, DT; Verma, A. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. eLife. 2022; 11.

Zhang, Y; Chen, X; Wang, H; Gordon-Mitchell, S; Sahu, S; Bhagat, TD; Choudhary, G; Aluri, S; Pradhan, K; Sahu, P; Starczynowski, D; Steidl, U; Maitra, A; Verma, A. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. Journal of Hematology and Oncology. 2022; 15(1):70.

Jones, LM; Starczynowski, DT. IKAROS and MENIN in synergy in AML. Nature Cancer. 2022; 3(5):528-529.

Barreyro, L; Sampson, AM; Ishikawa, C; Hueneman, KM; Choi, K; Pujato, MA; Chutipongtanate, S; Wyder, M; Haffey, WD; O'brien, E; Greis, KD; Nurmemmedov, E; Seibel, WL; Starczynowski, DT. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 2022; 14(635):eabb7695.

Azhar, M; Kincaid, Z; Kesarwani, M; Ahmed, A; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M. Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood advances. 2022; 6(4):1186-1192.

Muto, T; Guillamot, M; Yeung, J; Fang, J; Bennett, J; Nadorp, B; Lasry, A; Redondo, LZ; Choi, K; Gong, Y; Lujambio, A; Lowe, SW; Aifantis, I; Starczynowski, DT. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022; 29(2):298-314.e9.

Niederkorn, M; Ishikawa, C; M Hueneman, K; Bartram, J; Stepanchick, E; R Bennett, J; E Culver-Cochran, A; Bolanos, LC; Uible, E; Choi, K; Wunderlich, M; Perentesis, JP; M Chlon, T; Filippi, M-D; Starczynowski, DT. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. Leukemia. 2022; 36(2):438-451.

Aoyagi, Y; Hayashi, Y; Harada, Y; Choi, K; Matsunuma, N; Sadato, D; Maemoto, Y; Ito, A; Yanagi, S; Starczynowski, DT; Harada, H. Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes. Cancer Discovery. 2022; 12(1):250-269.

Bennett, J; Starczynowski, DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology. 2022; 29(1):8-19.